Reshaping the HIV treatment and prevention landscape

Focus on execution has increased speed to market following regulatory approval Time (Approval to Launch) 2013 Breo Ellipta 5 months Trelegy 2 months Nucala EGPA 50 days SHINGRIX 3 days Nucala AHA 2 days DOVATO 5 days Trelegy Asthma 19hrs Zejula PRIMA 4hrs 2017 2019 2020 Launch defined by first day of promotional activity in US gsk Cabenuva 1 day Benlysta LN 15hrs Blenrep 5hrs 2021 32

View entire presentation